サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1439708

敗血症診断 - 世界市場の考察、競合情勢、市場予測（2030年）

Sepsis Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
敗血症診断 - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の敗血症診断の市場規模は、2023年に6億4,448万米ドル、2030年までに11億1,482万米ドルに達し、2024年～2030年の予測期間にCAGRで9.60％の成長が見込まれます。市場は、COVID-19パンデミックの流行、老年人口の増加、結核などの細菌感染症の流行増加、先進技術を利用した敗血症診断製品に対する規制当局の承認の急増などのさまざまな要因によってプラス成長を示しています。したがって、市場は2024年～2030年の予測期間に大幅なCAGRでの成長が見込まれます。

敗血症診断の市場力学

敗血症診断市場の主な促進要因の1つは、COVID-19パンデミックの流行です。2022年7月1日に公表された世界保健機関（WHO）のデータによると、世界中でCOVID-19の症例が5億4,522万6,550件確認されています。このように、COVID-19は呼吸器系によく知られた影響を及ぼし、犠牲者の大半はさまざまな重症度の肺炎で入院を必要としますが、それにもかかわらず、その他の大半の臓器系に影響を及ぼす可能性があります。これは敗血症とウイルスによる直接侵襲が混在していることと一致します。そのため、敗血症診断では、感染や臓器障害の兆候を確認することが試みられており、これが敗血症診断に対する需要を押し上げ、予測期間（2024年～2030年）に敗血症診断市場全体を押し上げる可能性があります。

WHOが2023年に発表したデータによると、2015年～2050年に60歳以上の人口が12～22%から倍増し、2050年までに21億人に達すると推定されています。さらに、2030年までに世界の6人に1人が60歳以上となります。上記のデータによれば、80歳以上の人口は2020年～2050年に3倍に増え、4億2,600万人に達すると予測されています。さらに、年齢が上がるにつれて、免疫システムの弱体化により感染症にかかる機会も増え、敗血症診断の需要が高まる可能性があります。そのため、老年人口の増加は敗血症診断に対する需要を増加させ、予測期間（2024年～2030年）における敗血症診断市場全体を押し上げる要因となります。

したがって、前述の要因は敗血症診断に対する需要を増加させ、予測期間（2024年～2030年）における敗血症診断市場全体の成長を押し上げる可能性があります。

しかし、敗血症治療の高いコストや敗血症に関する認識および知識の不足が、世界の敗血症診断市場の成長を妨げる可能性があります。

進行中のCOVID-19パンデミックは、敗血症診断市場に若干プラスの影響を与えています。Global Sepsis Allianceによると、SARS-CoV-2は敗血症を引き起こします。このことは、ウイルス性敗血症がCOVID-19患者のもっとも一般的な合併症であり、死亡率の上昇につながるという近年の研究によって補強されています。COVID-19は患者の呼吸器系に影響を及ぼすため、患者の大部分はさまざまな重症度の肺炎で入院を必要としまが、それにもかかわらず、その他の大半の臓器系が影響を受ける可能性があります。これは敗血症とウイルスによる直接侵襲が混在していることと一致します。このように、COVID-19パンデミック症例の急増は敗血症診断の需要を押し上げ、COVID-19症例のさらなる増加は、敗血症の検出に用いるツール、試薬、検査キットの需要を増加させ、敗血症診断市場全体の急成長をもたらすと予測されます。

敗血症診断市場のセグメント分析

敗血症診断市場の製品タイプセグメントでは、器具・キットセグメントが2024年～2030年の予測期間に大きな伸びを示す見込みです。例えば、血液培養同定パネル（BCID）は、血流感染に関連する病原体や抗生物質耐性遺伝子を迅速かつ正確に同定することができます。これは、血流感染に関連する3つの抗生物質耐性遺伝子だけでなく、幅広い病原体（24種類）を調べることができます。さらに、およそ1時間、わずか2分の実地作業で、たった1回の検査で血液培養陽性10例のうち9例の感染を特定することができます。このように、BCIDに関連する利点は、市場における器具・キットの需要を押し上げ、予測期間の世界の敗血症診断市場全体の成長を促進する可能性があります。

当レポートでは、世界の敗血症診断市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 敗血症診断市場レポートのイントロダクション

第2章 敗血症診断市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価
  • 財務ベンチマーク

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 敗血症診断市場の主な要因の分析

  • 敗血症診断市場の促進要因
    • COVID-19パンデミックの流行
    • 老年人口の増加
    • 結核などの細菌感染症の流行
    • 先進技術を利用した敗血症診断製品に対する規制当局の承認の急増
  • 敗血症診断市場の抑制要因と課題
    • 敗血症治療の高いコスト
    • 敗血症に関する認識および知識の欠如
  • 敗血症診断市場の機会
    • 臨床検査とポイントオブケア検査に向けた新技術
    • 敗血症の診断に向けた新規バイオマーカーの同定

第5章 敗血症診断市場のポーターのファイブフォース分析

第6章 敗血症診断市場に対するCOVID-19の影響分析

第7章 敗血症診断市場のレイアウト

  • 製品タイプ別
    • アッセイ・試薬
    • 器具・キット
  • 技法タイプ別
    • 免疫測定法
    • 分子診断
    • フローサイトメトリー
    • 微生物
    • その他
  • 検査タイプ別
    • 臨床検査
    • ポイントオブケア検査
  • 病原体別
    • 細菌性
    • 真菌
  • エンドユーザー別
    • 病院
    • 病理研究所
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 敗血症診断市場：世界の企業シェア分析 - 主要3～5社

第9章 敗血症診断市場の企業と製品のプロファイル

  • BD
  • Cytovale (TM) Inc
  • Thermo Fisher Scientific Inc
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • bioMerieux SA
  • Danaher
  • T2 Biosystems Inc
  • Luminex Corporation
  • Bruker
  • Immunexpress Inc
  • Axis-Shield Diagnostics Ltd
  • Quidel Corporation
  • Siemens Healthcare Private Limited
  • EKF Diagnostics Holdings plc
  • Seegene Inc
  • Boditech Med Inc
  • Alifax S.r.l. Italy
  • Koninklijke Philips N.V
  • Response Biomedical Corp

第10章 KOLの見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis
  • Table 3: Sepsis Diagnostics Market in Global (2021-2030)
  • Table 4: Sepsis Diagnostics Market in Global by Product Type (2021-2030)
  • Table 5: Sepsis Diagnostics Market in Global by Techniques Type (2021-2030)
  • Table 6: Sepsis Diagnostics Market in Global by Test Type (2021-2030)
  • Table 7: Sepsis Diagnostics Market in Global by Pathogen (2021-2030)
  • Table 8: Sepsis Diagnostics Market in Global by End-User (2021-2030)
  • Table 9: Sepsis Diagnostics Market in Global by Geography (2021-2030)
  • Table 10: Sepsis Diagnostics Market in North America (2021-2030)
  • Table 11: Sepsis Diagnostics Market in North America by Country (2021-2030)
  • Table 12: Sepsis Diagnostics Market in the US (2021-2030)
  • Table 13: Sepsis Diagnostics Market in Canada (2021-2030)
  • Table 14: Sepsis Diagnostics Market in Mexico (2021-2030)
  • Table 15: Sepsis Diagnostics Market in Europe (2021-2030)
  • Table 16: Sepsis Diagnostics Market in Europe by Country (2021-2030)
  • Table 17: Sepsis Diagnostics Market in France (2021-2030)
  • Table 18: Sepsis Diagnostics Market in Germany (2021-2030)
  • Table 19: Sepsis Diagnostics Market in the United Kingdom (2021-2030)
  • Table 20: Sepsis Diagnostics Market in Italy (2021-2030)
  • Table 21: Sepsis Diagnostics Market in Spain (2021-2030)
  • Table 22: Sepsis Diagnostics Market in Russia (2021-2030)
  • Table 23: Sepsis Diagnostics Market in Rest of Europe (2021-2030)
  • Table 24: Sepsis Diagnostics Market in APAC (2021-2030)
  • Table 25: Sepsis Diagnostics Market in APAC by Country (2021-2030)
  • Table 26: Sepsis Diagnostics Market in China (2021-2030)
  • Table 27: Sepsis Diagnostics Market in Japan (2021-2030)
  • Table 28: Sepsis Diagnostics Market in India (2021-2030)
  • Table 29: Sepsis Diagnostics Market in Australia (2021-2030)
  • Table 30: Sepsis Diagnostics Market in South Korea (2021-2030)
  • Table 31: Sepsis Diagnostics Market in Rest of APAC (2021-2030)
  • Table 32: Sepsis Diagnostics Market in Rest of World (2021-2030)
  • Table 33: Sepsis Diagnostics Market in RoW by Region (2021-2030)
  • Table 34: Sepsis Diagnostics Market in Middle East (2021-2030)
  • Table 35: Sepsis Diagnostics Market in Africa (2021-2030)
  • Table 36: Sepsis Diagnostics Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis
  • Figure 3: Sepsis Diagnostics Market in Global (2021-2030)
  • Figure 4: Sepsis Diagnostics Market in Global by Product Type (2021-2030)
  • Figure 5: Sepsis Diagnostics Market in Global by Techniques Type (2021-2030)
  • Figure 6: Sepsis Diagnostics Market in Global by Test Type (2021-2030)
  • Figure 7: Sepsis Diagnostics Market in Global by Pathogen (2021-2030)
  • Figure 8: Sepsis Diagnostics Market in Global by End-User (2021-2030)
  • Figure 9: Sepsis Diagnostics Market in Global by Geography (2021-2030)
  • Figure 10: Sepsis Diagnostics Market in North America (2021-2030)
  • Figure 11: Sepsis Diagnostics Market in North America by Country (2021-2030)
  • Figure 12: Sepsis Diagnostics Market in the US (2021-2030)
  • Figure 13: Sepsis Diagnostics Market in Canada (2021-2030)
  • Figure 14: Sepsis Diagnostics Market in Mexico (2021-2030)
  • Figure 15: Sepsis Diagnostics Market in Europe (2021-2030)
  • Figure 16: Sepsis Diagnostics Market in Europe by Country (2021-2030)
  • Figure 17: Sepsis Diagnostics Market in France (2021-2030)
  • Figure 18: Sepsis Diagnostics Market in Germany (2021-2030)
  • Figure 19: Sepsis Diagnostics Market in the United Kingdom (2021-2030)
  • Figure 20: Sepsis Diagnostics Market in Italy (2021-2030)
  • Figure 21: Sepsis Diagnostics Market in Spain (2021-2030)
  • Figure 22: Sepsis Diagnostics Market in Russia (2021-2030)
  • Figure 23: Sepsis Diagnostics Market in Rest of Europe (2021-2030)
  • Figure 24: Sepsis Diagnostics Market in APAC (2021-2030)
  • Figure 25: Sepsis Diagnostics Market in APAC by Country (2021-2030)
  • Figure 26: Sepsis Diagnostics Market in China (2021-2030)
  • Figure 27: Sepsis Diagnostics Market in Japan (2021-2030)
  • Figure 28: Sepsis Diagnostics Market in India (2021-2030)
  • Figure 29: Sepsis Diagnostics Market in Australia (2021-2030)
  • Figure 30: Sepsis Diagnostics Market in South Korea (2021-2030)
  • Figure 31: Sepsis Diagnostics Market in Rest of APAC (2021-2030)
  • Figure 32: Sepsis Diagnostics Market in Rest of World (2021-2030)
  • Figure 33: Sepsis Diagnostics Market in RoW by Region (2021-2030)
  • Figure 34: Sepsis Diagnostics Market in Middle East (2021-2030)
  • Figure 35: Sepsis Diagnostics Market in Africa (2021-2030)
  • Figure 36: Sepsis Diagnostics Market in South America (2021-2030)
  • Figure 37: Market Drivers
  • Figure 38: Market Barriers
  • Figure 39: Market Opportunities
  • Figure 40: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0552

Sepsis Diagnostics Market By Techniques Type (Immunoassay, Molecular Diagnosis, Microbiology, Flow Cytometry, And Others), By Test Type (Laboratory Testing And Point Of Care Testing), By Product Type (Assays & Reagents And Instruments & Kits), By Pathogen (Bacterial, Fungal, And Others), By End-User (Hospitals, Pathology Laboratories, And Others), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing prevalence of covid-19 pandemic and a rise in the geriatric population

The global sepsis diagnostics market was valued at USD 644.48 million in 2023, growing at a CAGR of 9.60% during the forecast period from 2024 to 2030 to reach USD 1114.82 million by 2030. The sepsis diagnostics market is witnessing positive growth owing to various factors such as the increasing prevalence of the COVID-19 pandemic, a rise in the geriatric population, the increasing prevalence of bacterial infections such as tuberculosis, and the surge in the regulatory approvals for the technologically advanced sepsis diagnostics products. Therefore, the market for sepsis diagnostics is estimated to grow at a significant CAGR during the forecast period from 2024 to 2030.

Sepsis Diagnostics Market Dynamics:

One of the main drivers of the sepsis diagnostics market is the increasing prevalence of the COVID-19 pandemic. According to the World Health Organization (WHO) data published on 1 July 2022, there have been 545,226,550 confirmed cases of COVID-19 all over the world. Thus, COVID-19 has well-known effects on the respiratory system, with the majority of victims requiring hospitalization for pneumonia of various severity, nonetheless, almost all other organ systems can be impacted. This is consistent with a mix of sepsis and direct viral invasion. Therefore, sepsis diagnosis is attempted to verify or check the signs of any infection or organ damage with the disease, this can boost the demand for sepsis diagnostics, which could surge the sepsis diagnostics overall market forward during the forecast period (2024-2030).

Moreover, another key factor that is responsible for the growth of sepsis diagnostics is the rise in the geriatric population, as per the data published by the WHO in the year 2023, it was estimated that between the years 2015-2050 the number of citizens who aged 60 years and above will get doubled from 12-22% and will reach 2.1 billion by the year 2050. Adding to it, by the year 2030, one out of every six individuals worldwide will age 60 years or more. As per the above-mentioned data, the number of citizens aged 80 years or over is expected to get triple between the years 2020 and 2050 & will reach 426 million population. Furthermore, as age increases chances of suffering from infections also increase due to weakening immune systems which can boost the demand for sepsis diagnosis. Therefore, the rising geriatric population increases the demand for sepsis diagnostics, this surge the sepsis diagnostics overall market forward during the forecast period (2024-2030).

Therefore, the aforementioned factors could increase the demand for sepsis diagnostics, which can surge the growth of the overall sepsis diagnostics market during the forecast period from 2024-2030.

However, the high cost of sepsis treatment and the lack of awareness & knowledge about sepsis can hamper the global sepsis diagnostics market growth.

The ongoing COVID-19 epidemic has slightly positively impacted the sepsis diagnostics market. According to the Global Sepsis Alliance, SARS-CoV-2 causes sepsis. This is reinforced by a recent study, which found that viral sepsis is the most common complication in COVID-19 patients and is linked to increased mortality. Since, COVID-19 affects the patient's respiratory system, with the majority of patients requiring hospitalization for pneumonia of various severity, nonetheless, almost all other organ systems can be impacted. This is consistent with a mix of sepsis and direct viral invasion. Thus, the surge in COVID-19 pandemic cases boosted the demand for sepsis diagnostics, and the further increase in the COVID-19 cases is expected to increase the demand for tools, reagents, and test kits for sepsis detection, resulting in the surge in sepsis diagnostics overall market.

Sepsis Diagnostics Market Segment Analysis:

Sepsis Diagnostics Market by Techniques Type (Immunoassay, Molecular Diagnosis, Microbiology, Flow Cytometry, and Others), Test Type (Laboratory Testing and Point Of Care Testing), Product Type (Assays & Reagents, Instruments & Kits), Pathogen (Bacterial, Fungal, and Others), End-User (Hospitals, Pathology Laboratories, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the sepsis diagnostics market, the instruments & kits segment is expected to show significant growth during the forecast from 2024-2030. For instance, the Blood Culture Identification Panel (BCID), allows for the quick as well as precise identification of pathogens and antibiotic resistance genes associated with bloodstream infections. It looks for a wide range of pathogens (24) as well as 3 antibiotic resistance genes linked to bloodstream infections. Moreover, in roughly an hour, with only 2 minutes of hands-on work, it helps to identify infections in 9 out of 10 positive blood cultures with just one test. Thus, the benefits associated with the BCID, uplift the instruments & kits demand in the market, which could drive the growth of the overall global sepsis diagnostics market during the forecast period.

Furthermore, the developments in sepsis diagnostics products, are also expected to drive the market growth for it. For instance, in May 2022, BioMerieux, a global pioneer in-vitro diagnostics player, gained clearance from Health Canada for its BIOFIRE® Blood Culture Identification 2 (BCID2) Panel. In comparison to the original BIOFIRE® BCID Panel, the BIOFIRE® BCID2 Panel for quick molecular diagnosis of bloodstream infection contains numerous more pathogens, an extended list of antibiotic resistance genes, and many altered targets.

Hence, due to the interplay of the factors mentioned above, the sepsis diagnostics demand increases in the market, which can drive the growth of the global sepsis diagnostics market during the forecast period.

North America is expected to dominate the overall Sepsis Diagnostics Market:

Among all the regions, North America is expected to dominate the global sepsis diagnostics market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. Factors such as the increasing prevalence of bacterial infections such as tuberculosis and the surge in the regulatory approvals for technologically advanced sepsis diagnostics products are expected to increase the demand for sepsis diagnostics in the North America market.

According to the Centers for Disease Control and Prevention (CDC) published data in the year 2023, in the year 2023, the number of Tuberculosis (TB) cases in the United States was 7,860 which is equivalent to 2.4 per 100,000 persons. Thus, tuberculosis could lead to sepsis shock, which can result in improved demand for sepsis diagnostics, contributing to the conductive growth for sepsis diagnostics overall market forecast from 2024-2030.

Moreover, the surge in regulatory approvals for technologically advanced sepsis diagnostics products can boost the sepsis diagnostics overall market in the region. For instance, in February 2022, Noninvasix, which is expected to be the first company to non-invasively monitor central venous oxygenation announced that its LIVOx(TM) Central Venous Oxygenation Monitor has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for non-invasive, real-time, continuous or spot monitoring of central venous oxygen saturation (ScvO2) in adults at risk of septic shock in the United States.

Therefore, with the interplay of the factors mentioned above, there will be high demand for sepsis diagnostics, which would provide a conducive growth environment for the North American region in the sepsis diagnostics market.

Sepsis Diagnostics Market Key Players:

Some of the key market players operating in the sepsis diagnostics market include BD, Cytovale(TM) Inc, Thermo Fisher Scientific Inc, Abbott, F. Hoffmann-La Roche Ltd, bioMerieux SA, Danaher, T2 Biosystems Inc, Luminex Corporation, Bruker, Immunexpress Inc, Axis-Shield Diagnostics Ltd, Quidel Corporation, Siemens Healthcare Private Limited, EKF Diagnostics Holdings plc, Seegene Inc, Boditech Med Inc, Alifax S.r.l. Italy, Koninklijke Philips N.V, Response Biomedical Corp, and others.

Recent Developmental Activities in the Sepsis Diagnostics:

In January 2022, Pathogenomix, a next-generation sequencing, pathogen diagnostic company, was granted US Food and Drug Administration (FDA) Breakthrough Device Designation for its Patho-Seq assay. The assay is designed for the quick detection and identification of hundreds of clinically important bacteria for a wide range of clinical diseases and sample types, including sepsis from whole blood samples and bacterial meningitis from Cerebrospinal Fluid (CSF).

In November 2022, Immunexpress Inc, a molecular diagnostic company focusing on improving outcomes for suspected sepsis patients, announced that SeptiCyte RAPID has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). In hospitalized patients suspected of sepsis, the approved test helps to distinguish sepsis from infection-free systemic inflammation.

In March 2020, Immunexpress, Inc., a molecular diagnostics company focusing on improving outcomes for patients with suspected sepsis, announced that SeptiCyte® RAPID, their host response technology, has achieved CE Marking. SeptiCyte® RAPID combines SeptiCyte® technology with the Biocartis Idylla platform to provide actionable data in less than an hour, which allows doctors to make better patient care decisions. SeptiCyte® RAPID is a gene expression test that quantifies the relative expression levels of host response genes extracted from whole blood collected in the PAXgene® Blood RNA Tube using reverse transcription-polymerase chain reaction (PCR).

Key Takeaways from the Sepsis Diagnostics Market Report Study

  • Market size analysis for current sepsis diagnostics market (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the sepsis diagnostics market
  • Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint venture happened over the last 3 years
  • Key companies dominating the global sepsis diagnostics
  • Various opportunities available for the other competitor in the sepsis diagnostics market space.
  • What are the top-performing segments in 2023? How these segments will perform in 2030.
  • Which are the top-performing regions and countries in the current sepsis diagnostics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for sepsis diagnostics market growth in the coming future?

Target Audience who can be benefited from this Sepsis Diagnostics Market Report Study

  • Sepsis diagnostics providers
  • Research organizations and consulting companies
  • Sepsis Diagnostics-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in sepsis diagnostics
  • Various end-users who want to know more about the sepsis diagnostics market and latest technological developments in the sepsis diagnostics

Frequently Asked Questions for Sepsis Diagnostics:

1. What are Sepsis Diagnostics?

Sepsis diagnostics includes instruments, lab tests, various technologies, and others, which are used to diagnose sepsis by checking signs of infection or organ damage within the patient.

2. What is the market for Global Sepsis Diagnostics?

The global sepsis diagnostics market was valued at USD 644.48 million in 2023, growing at a CAGR of 9.60% during the forecast period from 2024 to 2030 to reach USD 1114.82 million by 2030.

3. What are the drivers for the Global Sepsis Diagnostics Market?

The sepsis diagnostics market is witnessing positive market growth owing to the factors such as the increasing prevalence of the COVID-19 pandemic, a rise in the geriatric population, the increasing prevalence of bacterial infections such as tuberculosis, and the surge in the regulatory approvals for the technologically advanced sepsis diagnostics products

4. Who are the key players operating in the Sepsis Diagnostics Market?

Some of the key market players operating in the Sepsis diagnostics market include BD, Cytovale(TM) Inc, Thermo Fisher Scientific Inc, Abbott, F. Hoffmann-La Roche Ltd, bioMerieux SA, Danaher, T2 Biosystems Inc, Luminex Corporation, Bruker, Immunexpress Inc, Axis-Shield Diagnostics Ltd, Quidel Corporation, Siemens Healthcare Private Limited, EKF Diagnostics Holdings plc, Seegene Inc, Boditech Med Inc, Alifax S.r.l. Italy, Koninklijke Philips N.V, Response Biomedical Corp, and others.

5. Which region has the highest share in Sepsis Diagnostics Market?

North America is expected to dominate the global sepsis diagnostics market. Factors contributing to the growth are the increasing prevalence of bacterial infections such as tuberculosis, and the surge in the regulatory approvals for technologically advanced sepsis diagnostics products contributes to the growth of the sepsis diagnostics market in the North America region.

Table of Contents

1.Sepsis Diagnostics Market Report Introduction

2. Sepsis Diagnostics Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment
  • 2.4. Financial Benchmarking

3. Regulatory Analysis

  • 3.1. The US
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Sepsis Diagnostics Market Key Factors Analysis

  • 4.1. Sepsis Diagnostics Market Drivers
    • 4.1.1. The Increasing Prevalence of COVID-19 Pandemic
    • 4.1.2. ARise in the Geriatric Population
    • 4.1.3. The Increasing Prevalence of Bacterial Infections such as Tuberculosis
    • 4.1.4. The Surge in the Regulatory Approvals for the Technologically Advanced Sepsis Diagnostics Products
  • 4.2. Sepsis Diagnostics Market Restraints And Challenges
    • 4.2.1. The High Cost of Sepsis Treatment
    • 4.2.2. The Lack of Awareness & Knowledge about Sepsis
  • 4.3. Sepsis Diagnostics Market Opportunities
    • 4.3.1. The Emerging Technologies for Laboratory and Point of Care Testing
    • 4.3.2. The Identification of Novel Biomarkers for Sepsis Diagnosis

5. Sepsis Diagnostics Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Sepsis Diagnostics Market

7. Sepsis Diagnostics Market Layout

  • 7.1. By Product Type
    • 7.1.1. Assays & Reagents
    • 7.1.2. Instruments & Kits
  • 7.2. By Techniques Type
    • 7.2.1. Immunoassay
    • 7.2.2. Molecular Diagnosis
    • 7.2.3. Flow Cytometry
    • 7.2.4. Microbiology
    • 7.2.5. Others
  • 7.3. By Test Type
    • 7.3.1. Laboratory Testing
    • 7.3.2. Point Of Care Testing
  • 7.4. By Pathogen
    • 7.4.1. Bacterial
    • 7.4.2. Fungal
    • 7.4.3. Others
  • 7.5. By End-User
    • 7.5.1. Hospitals
    • 7.5.2. Pathology Laboratories
    • 7.5.3. Others
  • 7.6. By Geography
    • 7.6.1. North America
      • 7.6.1.1. United States Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.1.2. Canada Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.1.3. Mexico Sepsis Diagnostics Market Size in USD Million (2021-2030)
    • 7.6.2. Europe
      • 7.6.2.1. France Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.2.2. Germany Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.2.3. United Kingdom Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.2.4. Italy Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.2.5. Spain Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.2.6. Russia Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.2.7. Rest of Europe Sepsis Diagnostics Market Size in USD Million (2021-2030)
    • 7.6.3. Asia-Pacific
      • 7.6.3.1. China Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.3.2. Japan Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.3.3. India Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.3.4. Australia Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.3.5. South Korea Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.3.6. Rest of Asia Pacific Sepsis Diagnostics Market Size in USD Million (2021-2030)
    • 7.6.4. Rest of the World (RoW)
      • 7.6.4.1. Middle East Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.4.2. Africa Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.4.3. South America Sepsis Diagnostics Market Size in USD Million (2021-2030)

8. Sepsis Diagnostics Market Global Company Share Analysis - Key 3-5 Companies

9. Sepsis Diagnostics Market Company and Product Profiles

  • 9.1. BD
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4. Product Listing
    • 9.1.5. Entropy
  • 9.2. Cytovale(TM) Inc
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4. Product Listing
    • 9.2.5. Entropy
  • 9.3. Thermo Fisher Scientific Inc
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4. Product Listing
    • 9.3.5. Entropy
  • 9.4. Abbott
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4. Product Listing
    • 9.4.5. Entropy
  • 9.5. F. Hoffmann-La Roche Ltd
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4. Product Listing
    • 9.5.5. Entropy
  • 9.6. bioMerieux SA
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4. Product Listing
    • 9.6.5. Entropy
  • 9.7. Danaher
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4. Product Listing
    • 9.7.5. Entropy
  • 9.8. T2 Biosystems Inc
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4. Product Listing
    • 9.8.5. Entropy
  • 9.9. Luminex Corporation
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4. Product Listing
    • 9.9.5. Entropy
  • 9.10. Bruker
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4. Product Listing
    • 9.10.5. Entropy
  • 9.11. Immunexpress Inc
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4. Product Listing
    • 9.11.5. Entropy
  • 9.12. Axis-Shield Diagnostics Ltd
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4. Product Listing
    • 9.12.5. Entropy
  • 9.13. Quidel Corporation
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4. Product Listing
    • 9.13.5. Entropy
  • 9.14. Siemens Healthcare Private Limited
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4. Product Listing
    • 9.14.5. Entropy
  • 9.15. EKF Diagnostics Holdings plc
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4. Product Listing
    • 9.15.5. Entropy
  • 9.16. Seegene Inc
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4. Product Listing
    • 9.16.5. Entropy
  • 9.17. Boditech Med Inc
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4. Product Listing
    • 9.17.5. Entropy
  • 9.18. Alifax S.r.l. Italy
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4. Product Listing
    • 9.18.5. Entropy
  • 9.19. Koninklijke Philips N.V
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4. Product Listing
    • 9.19.5. Entropy
  • 9.20. Response Biomedical Corp
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4. Product Listing
    • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us